MX2017003458A - Indazol ureas y metodo de uso. - Google Patents
Indazol ureas y metodo de uso.Info
- Publication number
- MX2017003458A MX2017003458A MX2017003458A MX2017003458A MX2017003458A MX 2017003458 A MX2017003458 A MX 2017003458A MX 2017003458 A MX2017003458 A MX 2017003458A MX 2017003458 A MX2017003458 A MX 2017003458A MX 2017003458 A MX2017003458 A MX 2017003458A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- indazole
- ureas
- formula
- disclosed
- Prior art date
Links
- -1 Indazole ureas Chemical class 0.000 title abstract 2
- 235000013877 carbamide Nutrition 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 abstract 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 abstract 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 abstract 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 abstract 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 abstract 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051024P | 2014-09-16 | 2014-09-16 | |
| US14/854,433 US9783527B2 (en) | 2014-09-16 | 2015-09-15 | Indazole ureas and method of use |
| PCT/US2015/050369 WO2016044386A1 (en) | 2014-09-16 | 2015-09-16 | Indazole ureas and method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017003458A true MX2017003458A (es) | 2017-10-31 |
Family
ID=55454105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003458A MX2017003458A (es) | 2014-09-16 | 2015-09-16 | Indazol ureas y metodo de uso. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9783527B2 (enExample) |
| EP (1) | EP3194404A1 (enExample) |
| JP (1) | JP2017527628A (enExample) |
| CA (1) | CA2961413A1 (enExample) |
| MX (1) | MX2017003458A (enExample) |
| WO (1) | WO2016044386A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018507900A (ja) * | 2015-03-13 | 2018-03-22 | アッヴィ・インコーポレイテッド | （インダゾール−４−イル）ヘキサヒドロピロロピロロン及び使用方法 |
| CN109824566A (zh) * | 2017-07-19 | 2019-05-31 | 浙江师范大学 | 一种(r)-2-(2,5-二氟苯基)吡咯烷的合成方法 |
| FI4069691T3 (fi) | 2019-12-06 | 2024-11-13 | Vertex Pharma | Substituoituja tetrahydrofuraaneja natriumkanavien modulaattoreina |
| CN115298173A (zh) | 2020-03-31 | 2022-11-04 | 田边三菱制药株式会社 | 羟基吡咯烷衍生物及其医药用途 |
| CN116396201A (zh) * | 2023-04-17 | 2023-07-07 | 南京优氟医药科技有限公司 | 一种（2r，4r）-4-氟代吡咯烷-2-羧酸的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06010852A (es) * | 2004-03-25 | 2007-01-16 | Memory Pharm Corp | Indazoles, benzotiazoles, benzoisotiazoles, bencisoxazoles y preparacion y usos de los mismos. |
| AU2005243147A1 (en) * | 2004-05-07 | 2005-11-24 | Memory Pharmaceuticals Corporation | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
| EP1844038A2 (en) * | 2004-11-24 | 2007-10-17 | Abbott Laboratories | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof |
| WO2007050732A1 (en) * | 2005-10-28 | 2007-05-03 | Abbott Laboratories | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR |
| RS53384B (sr) * | 2009-06-26 | 2014-10-31 | Novartis Ag | Derivati 1,3-disupstituisanog imidazolidin-2-on kao inhibitori cyp 17 |
| GB0917238D0 (en) * | 2009-10-01 | 2009-11-18 | Univ London | Blockade of voltage dependent sodium channels |
| WO2012095781A1 (en) * | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
| JP2015535252A (ja) * | 2012-10-26 | 2015-12-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおいて選択的活性を有するｎ−置換インダゾールスルホンアミド化合物 |
-
2015
- 2015-09-15 US US14/854,433 patent/US9783527B2/en active Active
- 2015-09-16 WO PCT/US2015/050369 patent/WO2016044386A1/en not_active Ceased
- 2015-09-16 EP EP15772129.1A patent/EP3194404A1/en not_active Withdrawn
- 2015-09-16 CA CA2961413A patent/CA2961413A1/en not_active Abandoned
- 2015-09-16 JP JP2017533748A patent/JP2017527628A/ja active Pending
- 2015-09-16 MX MX2017003458A patent/MX2017003458A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017527628A (ja) | 2017-09-21 |
| US20160075692A1 (en) | 2016-03-17 |
| WO2016044386A1 (en) | 2016-03-24 |
| CA2961413A1 (en) | 2016-03-24 |
| EP3194404A1 (en) | 2017-07-26 |
| US9783527B2 (en) | 2017-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016010056A (es) | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| MX2017005663A (es) | Tetrahidropiranos sustituidos y metodo de uso. | |
| WO2017177004A8 (en) | Tertiary amides and method of use | |
| TN2016000529A1 (en) | Substituted dihydroisoquinolinone compounds | |
| GEAP201814248A (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| PH12014502586A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| MX2016009581A (es) | Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso. | |
| MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
| NZ752587A (en) | Lsd1 inhibitors and medical uses thereof | |
| IN2014DN09347A (enExample) | ||
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| PH12017501422A1 (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| SG10201907291QA (en) | Monomethylfumarate prodrug compositions | |
| PH12017500029A1 (en) | 4,5-dihydroisoxazole derivatives as nampt inhibitors | |
| PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
| MX2017003458A (es) | Indazol ureas y metodo de uso. | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX377032B (es) | Compuestos de dihidroquinolinsulfonamida de alquilo. | |
| EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| PH12019500822A1 (en) | Crystalline forms of eravacycline | |
| PH12018500469A1 (en) | Sulfonamide compounds as voltage-gated sodium channel modulators | |
| WO2014160143A3 (en) | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders |